Author: Leo Hahn (Netherlands)
Co-authors: Michalis Georgiou, Maria M. van Genderen, Arthur A. Bergen, Bart P. Leroy, Michel Michaelides, Camiel J.F. Boon
Purpose
To describe the spectrum of retinal dystrophies associated with GUCY2D, and to identify potential clinical endpoints and optimal patient selection for future (gene) therapy.
Setting/Venue
This multicenter retrospective study included patients from from the Delleman archive, a large database for inherited eye diseases at the Amsterdam University Medical Centers (Amsterdam, the Netherlands), and various Dutch expertise center within RD5000 consortium, a national consortium for registering patients with retinal dystrophies. Data from additional patients were included from the University Hospital Ghent (Ghent, Belgium), as well as the Moorfields Eye Hospital (London, United Kingdom) and 3 other academic tertiary referral centers in the United Kingdom.
Methods
This study reviewed medical records of 52 affected patients from 30 unrelated families for medical history, symptoms, best-corrected visual acuity (BCVA), ophthalmoscopy, visual field, full-field electroretinography and retinal imaging (fundus photography, spectral-domain optical coherence tomography (SD-OCT), fundus autofluorescence).
Results
Patients had autosomal dominant cone-rod dystrophy (CORD; n=39; 75%) and autosomal recessive Leber congenital amaurosis (LCA; n=13; 25%). The mean follow-up time was 11.4±11.8 years for CORD and 5.7±4.4 years for LCA. The mean age at onset was 21.5±18.7 years and 0.4±1.0 years, respectively. For CORD, the mean Snellen BCVA at first visit was 0.25±0.22 (0.60±0.65 logMAR), and on average decreased with 0.07 (1.15 logMAR) per 10 years (p<0.003). In LCA patients, Snellen BCVA ranged from no light perception to 0.10 (1.00 logMAR). In CORD patients, the integrity of the ellipsoid zone (EZ) and external limiting membrane (ELM) on SD-OCT were significantly correlated with BCVA (Spearman’s r=-0.685 p=0.001 and r=-0.61 p=0.004, respectively).
Conlusions
LCA associated with GUCY2D mutations resulted in severe congenital visual impairment. GUCY2D-associated CORD showed a later onset and a relatively slow decrease of visual acuity, possibly suggesting a relatively large window of opportunity for future (gene) therapy. Severe visual impairment in the CORD group was generally reached in the 5th decade of life. The integrity of ELM and EZ may be suitable structural endpoints for future gene therapeutic studies in CORD.
Financial Disclosure
This research was supported by the ODAS foundation and the European Society of Retina Specialists (EURETINA Clinical Research Award 2019). This study was further supported by the Ghent University Special Research Fund (BOF15/GOA/011 to E.D.B. and BOF20/GOA/023 to E.D.B. and B.P.L.) and by the Ghent University Hospital Innovation Fund (NucleUZ to E.D.B.). E.D.B. (1802220N) and B.P.L. (1803821N) are Senior Clinical Investigators of the FWO. This study was performed as part of a collaboration within the European Reference Network for Rare Eye Diseases (ERN-EYE). E.D.B., C.C.W.K., L.I.v.d.B., C.B.H, B.P.L. & C.J.F.B. are members of ERN-EYE, which is co-funded by the Health Program of the European Union under the Framework Partnership Agreement No 739534 ‘ERN-EYE’. The sponsors or funding organizations had no role in the design or conduct of this research. Conflict of Interest: no conflicting relationship exists for any author.
Comments
-